1. Overview of Leprosy {#sec1}
======================

Leprosy is a chronic infectious disease of slow evolution caused by *Mycobacterium leprae*, which primarily affects the skin and peripheral nerves and may manifest in different clinical forms. There is strong evidence for a genetic basis for host disease per se susceptibility to and its subtypes \[[@B1]\].

Currently, Brazil is the second in the world in absolute number of cases of leprosy \[[@B2]\]. Patients with leprosy can show a broad spectrum of clinical symptoms. The tuberculoid form (TT) of leprosy consists of well-defined lesions, few bacilli, and vigorous cell-mediated immunity (CMI). On the other hand, lepromatous leprosy (LL) presents as many skin lesions with uncontrolled proliferation of leprosy bacilli and inefficient CMI. Borderline leprosy manifests clinically and immunologically with characteristics between the poles of the spectrum of leprosy and may be classified as 3 subtypes: borderline lepromatous (BL), borderline borderline (BB), and borderline tuberculoid (BT) \[[@B3]\].

Most individuals develop sufficient immunity against *M. leprae* with no signs of clinical disease. However, in a small proportion of exposed individuals, leprosy can manifest in an array of clinical forms, ranging from the localized tuberculoid to the systemic lepromatous disease. Typically, Th1- and Th2-type immune responses are initiated against the pathogen \[[@B4]\]. Evidence suggests that the incidence of infection in the population is probably much higher than the incidence of clinical leprosy, because a small proportion (about 5%) of infected individuals develop clinical symptoms and the rest can develop subclinical infections or heal spontaneously. This may be due in part to environmental factors such as nutrition, genetic differences, or bacterial \[[@B5]\].

The clinical and pathological spectrum of leprosy can be explained by genetic differences in host resistance. While some loci affect intrinsic susceptibility to LD, others modify the clinical form of the disease \[[@B6]\]. This review may help to clarify the mechanisms immunopathogenics of *M. leprae*. Studies of immune response genes in patients with leprosy can be used as a research tool in assisting genetic characterization of leprosy patients, thus allowing the determination of a possible association between these gene combinations and the development of leprosy and its clinical forms.

Leprosy has long been considered a complex disease. In the past few years, several studies have attempted to characterize genes associated with leprosy, as well as their contribution to the development of the various clinical forms. Immune response genes have been associated with pathogenesis of different forms of leprosy. This review discusses the role of the human leukocyte antigen (*HLA*), Killer cell immunoglobulin-like receptors (*KIRs*), and MHC class I chain-related (*MIC*) genes, as well as polymorphisms of cytokines, in leprosy and their implications for resistance and susceptibility to the disease.

2. Strategy for Screening and Selecting Studies {#sec2}
===============================================

This review about host genetic polymorphism studies, as well as the current status of genome-wide association studies and their influence on leprosy selected original articles carried out on humans that were found in the databases of PubMed (U.S. National Library of Medicine), LILACs (Latin American and Caribbean Center on Information in Health Sciences), and Google Scholar. The research period covered included the limit of databases until March 2013. There was no restriction regarding language. In the PubMed database MeSH (Medical Subject Heading) terms were used and in the LILACs descriptors were used. In order to retrieve articles of interest, free terms were used in the LILACS and Google Scholar. The MeSH terms, descriptors, and free terms were organized according to thematic groups: (i) HLA and Leprosy ("Leprosy" OR "Leprosy, Multibacillary" OR "Leprosy, Paucibacillary" OR "Leprosy, Tuberculoid" OR "Leprosy, Lepromatous" OR "Leprosy, Borderline" AND "HLA antigens/genetics"); (ii) KIR genes and Leprosy ("Leprosy" AND "Receptors, KIR"); (iii) MIC genes and Leprosy ("Leprosy" AND "MHC class I-related chain A"); (iv) Cytokine genes and Leprosy ("Leprosy" OR "Leprosy, Multibacillary" OR "Leprosy, Paucibacillary" OR "Leprosy, Tuberculoid" OR "Leprosy, Lepromatous" OR "Leprosy, Borderline" AND "Cytokines/genetics" OR "Receptors, Cytokine/genetics" OR "Chemokines/genetics"); (v) Genome-wide association study and Leprosy ("Leprosy" AND "Genome-Wide Association Studies"). The immune response genes, as *HLA*, *KIR*, *MIC,* and cytokines, and their association with leprosy were presented.

Screening the PubMed, LILACs, and Google Scholar databases identified 326 potentially relevant citations. Of these, 260 citations were excluded after evaluating the title and the abstract, because they did not comply with the inclusion criterion, no human, aim, originality, duplicate articles and that could not be downloaded or accessed in full length from journal archives. 64 articles related to immune response genes in association with leprosy and 19 articles more which were added from reference list, adding 83 original articles on human infections included in this review were selected.

The main characteristics of the studies selected, the populations under study, the target genes, the number of individuals, and the main finding for each are shown in Tables [1](#tab1){ref-type="table"}, [2](#tab2){ref-type="table"}, and [3](#tab3){ref-type="table"}.

3. HLA and Leprosy {#sec3}
==================

During infection caused by *M. leprae*, *HLA* alleles influence not only susceptibility and resistance to leprosy, but also the course of the disease. The main role of HLA molecules is to present peptides derived from *M. leprae*to T cells of the host \[[@B7]\]. An individual that has a particular combination of *HLA* alleles that are not linked to the peptide in an appropriate way, or for whom the HLA-peptide linkage does not elicit a proper lymphocyte response, will be more susceptible to infection than an individual that linked to the peptide in an appropriate way \[[@B8]\]. In patients whose HLA systems offer protection against the disease, these genes likely select and stimulate T cells to multiply and eliminate the agent via inflammatory cytokine production which destroy infected cells \[[@B7], [@B9]\]. Several studies have consistently reported the involvement of *HLA* alleles and haplotypes, mainly of class II genes, as important genetic factors controlling susceptibility to different forms of leprosy \[[@B9]\]. According to Ridley and Jopling (1966), the clinical manifestation of leprosy depends on the type of immune response that is initiated by the host and the balance between T-helper (Th)1 and Th2 responses may be partially controlled by the mechanism of antigen presentation involving HLA molecules \[[@B10], [@B9]\]. The tuberculoid (TT) form of leprosy is associated with a Th1 (cellular) immune response, characterised by the production of proinflammatory cytokines that can participate in the clearance of the bacillus. However, the lepromatous (LL) form of leprosy is associated with a Th2 (humoral) immune response, which is characterised by an immunosuppressive cytokine environment, making this type of response problematic for the host \[[@B3], [@B11]\].

4. Classical *HLA* Class I Genes {#sec4}
================================

Several studies comparing *HLA* class I gene frequencies in leprosy cases and controls have found associations either with the polar forms of leprosy or with LD. Nevertheless, results have been inconsistent.

Earlier, association studies showed HLA-Aw21 as a factor of susceptibility to TT in Ethiopian patients \[[@B12]\], while HLA-A9 in India, HLA-A2 in Thailand and Korea as a factor of resistance to leprosy \[[@B13], [@B14], [@B15]\]. In leprosy patients from Iran, HLA-B35 antigen was increased, while HLA-A1 was decreased in LL patients \[[@B16]\]. The HLA-B40 antigen and HLA-A2-B40, HLA-A11-B40, and HLA-A24-B40 haplotypes were frequent among Indian leprosy patients \[[@B17]\], while HLA-A11 and HLA-A33 were increased among Korean LL patients \[[@B15]\].

In Indian patients, an increasing frequency of HLA-A11 \[[@B18]\] and HLA-B60 \[[@B7]\] antigens have been observed in LL patients. In southern Chinese, significantly decreased HLA-B46 was found in multibacillary leprosy \[[@B19]\]. In a Turkish LL case-control study, HLA class I serotypes A9, A10, Bw4, Bw6, Cw1, and Cw2 were significantly overrepresented, and serotypes A3 and B49 were significantly underrepresented in the LD patients \[[@B20]\].

Subsequently, with the advent of molecular genotyping, *HLA* class I alleles were determined in multibacillary leprosy patients, resulting in a positive association with *HLA-A*\**02:06*, *A*\**11:02*, *B*\**18:01*, *B*\**51:10*, *C*\**04:07*, and *C*\**07:03* alleles, and a negative association with *C*\**04:11* \[[@B8]\]. The *A*\**11-B*\**40* haplotype was increased in multibacillary leprosy patients compared to controls \[[@B21]\].

Recent studies have shown a positive association between LD and *HLA-A*\**11*, *HLA-B*\**38*, and *HLA-C*\**12*, as well as a negative association with *HLA-C*\**16*. When groups were stratified, *HLA-B*\**35* and *HLA-C*\**04*were shown to be protective against lepromatous leprosy, while *HLA-C*\**07* was shown to be a susceptibility variant \[[@B22]\]. Further, the allele *HLA-C*\**15:05* was related to phenotype LD in certain populations from India and Vietnam \[[@B23]\]. [Table 1](#tab1){ref-type="table"} summarizes these findings.

5. Classical *HLA* Class II Genes {#sec5}
=================================

According to some studies, the main restriction determinants for *M. leprae* reside on DR, and not DP or DQ molecules \[[@B25], [@B26]\]. The HLA-DR2 molecule \[[@B24], [@B15], [@B7], [@B23]--[@B29], [@B30], [@B31]\], later identified as *DRB1*\**15* and *DRB1*\**16* variants, is primarily associated with leprosy (LD or different clinical forms) in Indian, Japanese, Brazilian, and Chinese patients \[[@B33]--[@B35], [@B36], [@B37], [@B10], [@B38], [@B39], [@B32], [@B40]\].

In Indian patients, *DRB1*\**15:02* was associated with TT \[[@B29], [@B33]\], whereas *DRB1*\**15:01* was associated with LL \[[@B33]\]. *DRB1*\**15:01* and \**15:02* alleles differ from each other by a single amino acid at codon 86. Class II molecules have polymorphic pockets that accommodate the side chains of bound peptides. The codon 86 residue lies in binding pocket 1. In another Indian study, both *DRB1*\**15:01* and \**15:02* were found to be associated with tuberculoid leprosy, \[[@B35]\] indicating that the residue in pocket 1 may not be involved in determining the outcome of leprosy infection. Instead, it appears that certain residues that contribute to the net charge in the putative peptide-specific binding pocket 4 may be more important \[[@B41]\]. It is hypothesized that net negative or neutral charges in binding pocket 4 cause poor binding of the DRB1 molecule to *M. leprae* antigens. HLA molecules with the highest affinity to peptide produce the greatest T-cell proliferation and IFN-*γ* response \[[@B42]\], and the peptide presentation by low affinity class II molecules may result in muted cell-mediated immunity \[[@B41]\]. Alternatively, peptide presentation by specific class II molecules may result in activation of suppressor/regulatory T-cells \[[@B43]\].

Studies involving HLA-DRB1 have found a link between innate and T-cell-mediated immunity \[[@B44], [@B45]\], and results obtained from a multiple sclerosis study show that the presence of a VDRE (vitamin D response elements) in the proximal promoter region of the *HLA-DRB1* gene increased gene expression and imparts 1,25-(OH)2-D3 (Vitamin D) sensitivity to the *DRB1*\**15:01* allele \[[@B45]\].

These observations point to the need to apply this possibility of association between these genetic variants and leprosy pathogenesis, since vitamin D, itself, may have a direct effect on leprosy through its receptors, VDR, or may influence leprosy through indirect effects \[[@B45]\].

Amino acid residues involved in the peptide binding groove of *HLA-DRB1* alleles were examined in three Nigerian ethnic groups (Bini/Igbo, Yoruba, and Efik) with leprosy. Nine positively charged motifs and 2 others with neutral charge in the peptide binding groove were detected. These motifs were more frequent in leprosy patients than was expected by chance. In contrast, 5 motifs with negative or "modified" neutral charges in the pocket were negatively associated with leprosy. Therefore, the clinical outcome of infection by *M. leprae* is largely determined by a shared epitope in *DRB1* alleles characterized by several motifs \[[@B41]\].

In leprosy patients from a Javanese population in Yogyakarta, Indonesia, *HLA-DRB1*\**02* was associated with susceptibility to LL, while *HLA-DRB1*\**12* was associated with resistance \[[@B46]\]. Risk for leprosy associated with the *DRB1*\**10* allele has been described in Turkish, Vietnamese, and Brazilian populations \[[@B20], [@B38]\], whereas the *HLA-DRB1*\**14* allele was associated with the TT group in a population from north-eastern Brazil \[[@B40]\] and *DRB1*\**14:01* and *DRB1*\**14:06* were associated with leprosy per se in Argentinean population \[[@B47]\]. A protective effect on leprosy has been described for *DRB1*\**04* in Brazilian, Korean, Japanese, Vietnamese, Argentinean, and Taiwanese populations \[[@B15], [@B36], [@B48], [@B38], [@B49]\]. Associations between HLA class II and leprosy are summarized in [Table 2](#tab2){ref-type="table"}.

The HLA complex has been studied in leprosy patients due to the direct involvement of these alleles in the immune response. In terms of both infection control and the manifestation of the different clinical forms, investigation of *HLA* genes may elucidate mechanisms of susceptibility and resistance, as well as disease course.

Even though genetic epidemiology data in leprosy involving alleles *HLA* is extensive, results should be cautiously interpreted due to the strong linkage disequilibrium across the alleles in this region, the common occurrence of weak study designs, and publication bias of positive results. Furthermore, functional data to support these associations are required.

6. *KIR*Genes and Leprosy {#sec6}
=========================

Killer cell immunoglobulin-like receptors (KIRs) are members of a group of regulatory molecules found on natural killer (NK) cells. These proteins are encoded by a complex of genes located in the Leukocyte Receptor Complex on chromosome 19p13.4, which has many polymorphisms that may be related to resistance to infection \[[@B52]\]. Known roles of NK cells include modulation on the immune system by the production of cytokines, as well as direct elimination of infected cells \[[@B53]\]. KIR molecules are either activating or inhibitory to NK cells. Inhibitory molecules (KIR2DL1, 2DL2, 2DL3, 2DL4, 2DL5, 3DL1, 3DL2, and 3DL3) function via the well-documented immunoreceptor tyrosine-based inhibitory motifs (ITIMs) \[[@B53]\]. The phosphorylated ITIMs serve as efficient recruitment points for the cytosolic protein tyrosine phosphatases, SHP-1 and SHP-2, resulting in the dephosphorylation of substrates critical for cellular activation \[[@B53]\].

Activating receptors (2DS1, 2DS2, 2DS3, 2DS4, 2DS5, and 3DS1) have truncated cytoplasmic domains lacking ITIMs but possess a charged residue (ITAMs) in their transmembrane domains that mediates interaction with the DAP-12 signal transduction chain. DAP-12 is a member of the immunoglobulin super family encoded at the centromeric end of the LRC. DAP-12 activation then leads to enhanced degranulation and production of cytokines and chemokines \[[@B54]\]. Studies performed over the last few years have revealed extensive diversity at the *KIR* gene locus, stemming from both its polygenic and multiallelic polymorphisms \[[@B55], [@B56]\].

Biologically, NK cell reactivity against target cells is partially based on the presence of KIRs and their cognate ligands, the HLA class I molecules. Some combinations of HLAs and KIRs may result in activation or inhibition of NK cells. It seems likely that NK receptor variants may be risk factors for infectious diseases in addition to HLA variants, as has been reported in leprosy. To further elucidate the balance between inhibitory and activating KIRs in the context of disease pathogenesis, continued epidemiological analysis of KIRs and disease should be pursued \[[@B57]\].

There are many studies showing the influence of *KIR* genes and their ligand pairs on the role of various infectious diseases. However, to the best of our knowledge only one study has explored the role of *KIR* genes in the pathogenesis of leprosy \[[@B54]\].

According to Franceschi et al. \[[@B54]\], a significant difference between *KIR*genes in TT and LL patients has been observed. In TT patients, the frequency of *KIR2DS3* (38.1%) was significantly higher than in LL patients (18.5%), and the frequency of *KIR2DS2* showed a trend of being higher in TT patients (61.9%) compared to LL patients (43.1%). *KIR2DS3* and *KIR2DS2*are activator genes in linkage disequilibrium. Tuberculoid patients with both activator genes could develop a better NK-cell activation and then a more efficient cell-mediated immune response, with a milder manifestation of the disease. When KIR inhibitor genes and their HLA ligands were analyzed, TT patients had low frequencies of these KIRs in association with their correlated ligands, conferring a reduced NK cell inhibition and resulting in a protective mechanism against the most severe forms of the disease.

In the same study, patients with the form BB were observed to have a higher frequency of *KIR3DL2*-*A3/11* genes (40.0%) compared to the control group (24.6%) and LL patients (20.0%). In contrast, a reduced frequency of *KIR2DL1* with the *C2* as a ligand was found compared to TT patients (48.9% versus 76.3%) and the control group (48.9 versus 66.4%). This balance between these interactions may explain the undefined characteristics observed in BB patients.

According to Parham \[[@B58]\], of the family of KIR2DL molecules, KIR2DL1 with the ligand C2 is the most potent inhibitor. In the study by Franceschi et al. \[[@B54]\], an increased frequency of homozygous *C2*/*C2* was observed in TT patients compared to BB patients and to control group, suggesting that TT patients may be more susceptible to infection than the control group.

7. *MICA*Genes {#sec7}
==============

In 1994, Bahram et al. \[[@B59]\] and Leelayuwat et al. \[[@B60]\] independently identified a new set of *loci* called MHC class I chain-related genes (*MIC*). The *MIC*family has two members*, MICA*and *MICB*, and 5 pseudogene members: *MICC*, *MICD*, *MICE*, *MICF,*and *MICG*. *MICA*is located at the centromeric end of the classical *HLA*class I region, approximately, 46.4 kb from *HLA-B* \[[@B61]\]. *MIC*genes encode a cell-surface glycoprotein of 383 amino acids, which is expressed in keratinocytes, fibroblasts and gastrointestinal epithelium, and several other cell types \[[@B62]\]. Exons 2, 3, and 4 of the gene encode three extracellular domains (*α*1, *α*2, and *α*3, resp.), while exon 5 encodes the transmembrane domain. Amino acid sequence alignments with classical HLA class I chains reveal between 15 and 21% homology in *α*1 and *α*2 domains but between 32% and 36% homology in the *α*3 domain \[[@B59]\].

Studies have shown that MICA works as a ligand for NK cells, *γδ* T cells, and *αβ* CD8+ T cells, which express a common activating NK cell receptor NKG2D \[[@B63]\]. NKG2D recognizes the human MICA protein in conjunction with a transmembrane signaling adaptor protein, DNAX-activation protein (DAP) \[[@B64]\].

Within exon 5, there is a short tandem repeat (STR) of GCT triplets in varying lengths \[[@B65]\]. This STR is commonly referred to as an "A" followed by the number of GCT repeats and occasionally a "1", which reflects the presence of a G insertion (e.g., *A4*, *A5*, and *A5.1*). This information about exon 5 in *MICA*may therefore be of importance as polymorphisms in the transmembrane domain were correlated with the induction of autoreactive CD8+ cytotoxic T lymphocytes \[[@B66]\]. In addition, a G insertion within the exon 5 STR leads to a premature stop codon, which is translated into a truncated protein with impaired function \[[@B67]\].

Similar to classical *HLA*, *MICA*displays a high degree of allelic polymorphism within the nonclassical *HLA*gene *loci*, which results in MICA polymorphic residues that are positioned on the outer edge of an antigen-binding cleft, unlike MHC class I molecules \[[@B68]\], and they may have a role in the innate immune response to infection.

Since MIC expression is inducible by heat, viral infection, inflammation, and DNA damage, the molecules may be markers of stress in cells.

8. *MICA*and Leprosy {#sec8}
====================

Studies linking *MIC*genes and leprosy are limited. Wang et al. \[[@B19]\] analyzed 69 southern Chinese leprosy patients and observed that *MICA-A5* allele showed a tendency to be negatively associated to multibacillar leprosy but not to paucibacillar. In the same group of patients, a negative association between the *HLA-B46*/*MICA-A5* haplotype and leprosy was found, suggesting that the *HLA-B46*/*MICA-A5* haplotype is significantly associated with resistance to leprosy. On the other hand, Tosh et al. \[[@B37]\] provided strong evidence that truncated MICA protein encoded by the *MICA-A5.1* allele plays a role in leprosy susceptibility in South Indian families.

In the study performed in southern Brazil by Sacramento et al. \[[@B68]\], 223 patients with leprosy from towns in the northern and northwestern regions of the State of Paraná participated. *MICA*\**002*, \**008*, \**004,* and \**009* alleles were the most frequent, totalling 74.0% of all alleles in leprosy patients and 68.5% in the control group. There was only one significant difference: the frequency of the *MICA*\**027* allele was higher in the control group compared to patients with LD. The alleles *MICA*\**010* and *MICA*\**027* had significant differences in multibacillary (LL, BB, and BL) patients compared to the control group. For the paucibacillary (TT and BT) group, no difference was found.

In this context, the *MICA*\**027* allele was associated with protection against leprosy *per se*and the multibacillary subtypes. Individuals with the *MICA*\**027* variant have normal expression of A5, a transmembrane domain which enables the interaction between MICA and NKG2D, activating NK cells.

Finally, these results suggest the influence of *MICA*alleles in the development of the leprosy and their clinical forms and need to be replicated.

9. Cytokines {#sec9}
============

An important factor that directs the clinical course of leprosy is the presence of proinflammatory and anti-inflammatory cytokines. Paucibacillary patients show a pattern of CMI of the Th1 type, which is characterized by the production of IFN-*γ*, IL-2, IL-7, IL-12, IL-15, and IL-18 in skin lesions. Conversely, multibacillary patients present a Th2 response with production of TGF-*β*1, IL-4, IL-5, and IL-10 in skin lesions with high antibody production, but insufficient CMI \[[@B69], [@B70]\].

SNPs are the most abundant source of genetic variation in the human genome, which can lead to differences in expression of proteins, causing structural and functional changes. Linking SNPs with the phenotypes of human diseases has great potential for direct clinical application, providing more accurate genetic markers for diagnosis and prognosis, and possibly new therapeutic targets \[[@B71]\]. Some SNPs in cytokine genes have been described as important genetic factors in the occurrence of different clinical forms of leprosy.

10. Cytokines and Leprosy {#sec10}
=========================

The gene encoding tumor necrosis factor (*TNF*) is located in the MHC region on chromosome 6. This cytokine exists in soluble and transmembrane forms \[[@B72]\] and is produced by cells of the immune system, tumor cells, and other cell types in response to inflammatory stimuli, infection, or stress \[[@B72]\]. There is ample evidence of the involvement of cytokines, especially tumor necrosis factor-alpha (TNF-*α*), in the immune response to leprosy. They may have a beneficial role in host defense but, if produced at high levels, cause tissue damage \[[@B73]\].

Studies conducted in Brazil by Santos et al. \[[@B74]\], Moraes et al. \[[@B75]\], Santos et al. \[[@B76]\], Franceschi et al. \[[@B77]\], and Cardoso et al. \[[@B78]\] indicated the association of *TNF-308A* (rs1800629) allele with a protective effect against the development of the disease. Vanderborght et al. \[[@B73]\], in a study in Rio de Janeiro, observed that patients possessing an A allele in the promoter region of *TNF-308* had a lower bacteriological index (BI), whereas the carriers of the A allele in the promoter region of *TNF-238* (rs361525) had higher BI.

A study in Nepal in 2010 by Sapkota et al. \[[@B79]\] showed results similar to Brazilian studies in relation to *TNF-308A* allele. However, studies conducted in an Indian and Thai populations \[[@B80], [@B81]\] showed a higher frequency of *TNF2* allele (with substitution G\>A at position 308 in the *TNF*promoter region) in lepromatous and multibacillary patients, respectively, compared to the control group, indicating that this allele is associated with susceptibility to this form of disease. Nevertheless, a linkage study conducted in six French Polynesian families for Levée et al. \[[@B82]\] found no evidence of linkage between the loci *G1M*, *G2M*, *KM*, *IL-1* beta, *TNF-alpha* (1, 2), and *TNF-alpha* (A, G) and leprosy.

In the study multicase leprosy families from north-eastern of Brazil, the combined segregation and linkage analysis to the major locus showed strong linkage to *HLA* class II and tumour necrosis factor genes. Extended transmission disequilibrium testing, using multiple affected family members, demonstrated that the common allele *TNF*\**1* of the −308 promoter region polymorphism showed linkage and/or association with disease per se, at a high level of significance. Two locus transmission disequilibrium testing suggested susceptibility (*TNF*\**1/LTA*\**2*) and protective (*TNF*\**2/LTA*\**2*) haplotypes in the class III region. Taken together the segregation and HLA analyses suggest the possibility of more than one susceptibility locus to leprosy in the MHC \[[@B50]\].

In a recent study in Mexico \[[@B83]\], no association was found between *TNF-308G/A*and leprosy, suggesting that other polymorphisms may be important in susceptibility to leprosy in this population. However, a study performed in a population from Northern India \[[@B84]\] provided further evidence for the role of variants *BAT1-LTA-TNF-BTNL2*genes in susceptibility to leprosy. According to authors, the combination of low T-cell inhibition status of BTNL2, less inhibition of TNF by BAT1, and low TNF expression may provide protection from leprosy, which may be stronger in the presence of high TNF producer allele genetic background.

Interleukin 10 (IL-10) is a cytokine produced by monocytes and activated T cells. It is deeply involved in the regulation of inflammatory and immunological reactions. Its effects do not only affect the immune system but can influence many physiological processes, including angiogenesis, tumorigenesis, and infection. Several polymorphisms have been observed in the *IL10* gene, including 6--11 CA repeats-microsatellite polymorphisms, and three point mutations: −1082 (G/A) (rs1800896), −819 (C/T) (rs1800871), and −592 (C/A) (rs1800872) \[[@B85]\].

Recently, in Mexican patients, Velarde-Félix et al. \[[@B83]\] found no statistically significant difference in the frequency of *IL10*−*819C* allele in patients and controls. However, in a Brazilian population, Pereira et al. \[[@B86]\] had reported that the *IL10*−*819T* allele was associated with leprosy in both a case-control study and in a meta-analysis.

Similar results were found in another Brazilian population of Rio de Janeiro by Santos et al. \[[@B76]\], where the *IL10*−*819TT* genotype was significantly higher in patients than in healthy controls, and the frequency of the *IL10*−*819T* SNP was greater in paucibacillary patients compared to multibacillary or among control subjects. However, in Colombian patients, the genotypes C/C and C/T in the SNP −819 and C/C and C/A in the −592 SNP were positively associated to leprosy. The haplotypes −819C−592C and −1082A−819C−592C showed significant association and these same haplotypes in homozygosis conditions were also associated with leprosy \[[@B87]\].

In another study, Moraes et al. \[[@B88]\] observed that in patients from the same Brazilian region the haplotype *IL10*−*3575A/*−*2849G/*−*2763C*was associated with resistance to leprosy and development of more severe forms of the disease, and that the haplotype *IL10*−*3575T*/−*2849A*/*2763C* was associated with susceptibility to LD.

In a study conducted in India, Malhotra et al. \[[@B89]\] observed that the extended haplotype *IL10*−*3575T/*−*2849G/*−*2763C/*−*1082A/*−*819C/*−*592C* conferred resistance to leprosy *per se* and to development of more severe forms of disease, whereas the haplotype *IL10*−*3575T/*−*2849G/*−*2763C/*−*1082A/*−*819T/*−*592A* was associated with the risk of developing a more severe form of the disease. A study in a population of southern Brazil by Franceschi et al. \[[@B77]\] showed a lower frequency of haplotype *IL10*−*1082G/*−*819C/*−*592C* in patients with the lepromatous form of the disease compared to the control group. The results of these studies strongly suggest the involvement of SNPs in the promoter region of the *IL10* gene in leprosy.

IL-12 consists of two covalently linked subunits: p35 and p40. Antigen-presenting cells, specifically dendritic cells and macrophages, are the main producers of this cytokine. The effects of IL-12 are mainly controlled by the level of transcription of p40 and expression of IL-12R. IL-12 is produced quickly after infection and acts as a proinflammatory cytokine by inducing IFN-*γ* production and enhancing the proliferation and cytotoxicity of NK and T cells \[[@B90]\].

According to Morahan et al. \[[@B91]\], in Indian patients, subjects with leprosy were less likely to have the 3′UTR genotype associated with lower IL-12B expression. However, in Korean patients, Lee et al. \[[@B92]\] found no significant differences in allele frequencies of *IL12RB1* between leprosy patients and the control group \[[@B92]\]. Now, in relation to gene in the 5′ flanking region of *IL12RB2*, Ohyama et al. \[[@B93]\] determined the functional effects of these SNPs on NK-cell activity, including IFN-*γ* production and *IL-12RB2* gene expression. The results suggest that these SNPs in *IL12RB2* have differential effects on cellular activation of T and NK cells \[[@B93]\].

In Western Mexico, Alvarado-Navarro et al. \[[@B94]\] found that the 1188A/C polymorphism in the 3′UTR of *IL12p40* gene was associated with greater susceptibility to lepromatous leprosy, independent of the expression levels of IL-12 p40. Conversely, Jesús Salvador et al. \[[@B95]\] in a study with Mexican patients found no significant association between genotype and allele frequencies of the 1188A/C polymorphism and lepromatous leprosy \[[@B95]\].

Recently, Liu et al. \[[@B96]\] conducted a multiple-stage genetic association study in leprosy patients from China and discovered associations implicating *IL18RAP/IL18R1* (rs2058660) and*IL12B* (rs6871626) as susceptibility genes for leprosy.

The *IFNG* gene encodes the IFN-*γ* cytokine, which plays a key role in host defense against intracellular pathogens. SNPs in *IFNG* were evaluated in several epidemiological studies; the SNP *INFG+874T/A* (rs2430561), more specifically, the allele *INFG+874T* has been associated with protection against infectious diseases \[[@B97]\].

In patients from São Paulo and Rio de Janeiro, two independent studies conducted by Cardoso et al. \[[@B98]\] showed that the *INFG+874T* allele conferred protection against leprosy. Recently, in Chinese patients, Wang et al. \[[@B99]\] found no association between *INFG+874T/A* and leprosy. However, the variant rs3138557 in the *IFNG*gene had many CA-repeat alleles and they observed that the alleles *INFG* (10CA), INFG (13CA), and *INFG* (15CA) had a higher frequency in patients, especially in multibacillary compared to the control group (3.2 versus 0.6%; 21.3 versus 18.6%; and 21.8 versus 18.0%, resp.), and that the allele *INFG* (17CA) was more frequent in paucibacillary patients than in controls (2.8 versus 1.2%). In patients from Amazonas state, Brazil, there were no significant differences between patients and control subjects, as well as according to Ridley-Jopling classification. However, the A/A genotype and the allele *INFG* (16CA) were significantly associated with paucibacillary compared to multibacillary patients \[[@B100]\].

In a population of Brazilian patients, Reynard et al. \[[@B101]\] observed that a higher frequency of alleles *INFG* (15CA),*INFG* (16CA), and *INFG*(17CA) was positively associated with leprosy, which indicates that the *IFNG* gene polymorphism may contribute to the course of infection.

In Korean patients, no significant differences were found in allele frequencies*IFNGR1* (interferon *γ* receptor 1) between leprosy patients and the control group \[[@B92]\]. However, a case report showed that the *IFNGR1* polymorphism at position −56T/C was positively associated with an increased susceptibility to leprosy, in Iranian children of the same family \[[@B102]\].

Polymorphisms in the *IL4* gene influence the production of IL-4, an important anti-inflammatory cytokine generated by T-helper type 2 (Th2) cells, which have multiple roles in the immune system. Three polymorphisms in *IL4* have been described: a single base polymorphism −590T/C (rs2243250) in the promoter region, polymorphism +33C/T (rs2070874) in exon 1, and type VNTR polymorphism (variable number of tandem repeat) in intron 3. In a Chinese study, Yang et al. \[[@B103]\] observed that the*IL4−590T/C*and C/C genotypes, and the −590C allele were less frequent in leprosy patients than in the control group (25 versus 29.9%; 3.9 versus 7.5%; and 16.4 versus 22.5%, resp.), suggesting that the allele *IL4*−*590C* is associated with resistance to leprosy in this population.

Interleukin-6 (IL-6) is a pleiotropic cytokine, produced by different cell types, such as macrophages, fibroblasts, and endothelial cells. IL-6 plays an important role in a wide range of processes, such as immune response, acute phase reactions, and hematopoiesis \[[@B104]\].

Recently, in a case-control study, Sousa et al. \[[@B105]\] observed a correlation between plasma levels of IL-6 and *IL6* genotypes in patients with Type-2 reactions in leprosy. Type-1 and Type-2 leprosy reactions are aggressive inflammatory episodes with highly variable incidence rates across populations but affect up to 50% of leprosy patients. Identification of genetic factors predictive of leprosy reactions could have a great impact on prevention strategies.

A study conducted in MassARRAY platform, carried out by Aggarwal et al. \[[@B106]\], in the Indian population investigated the association of 51 SNPs in anti-inflammatory cytokine and receptor genes with susceptibility to leprosy. Significant associations with leprosy were observed for 8 polymorphisms (rs1800871, rs1800872, and rs1554286 of *IL10*, rs3171425 and rs7281762 of *IL10RB*, rs2228048 and rs744751 of *TGFBR2*, and rs1800797 of *IL6*). The study revealed a greater association of these polymorphisms with the risk for leprosy than those obtained for any SNP studied individually. This provides an interesting insight on the cumulative polygenic host component that regulates leprosy pathogenesis \[[@B106]\]. [Table 3](#tab3){ref-type="table"} summarizes these findings.

Studies have been carried out in order to investigate a possible combined effect of *HLA*genes and cytokines genes in leprosy, more specifically *TNF* gene and *HLA* class II \[[@B50], [@B80]\]. However, the results are inconsistent. The first study by Roy et al. \[[@B80]\] did not find linkage disequilibrium between *TNF2* allele and *HLA* class II, showing that these genes appear to be independent, whereas Shaw et al. \[[@B50]\] showed strong linkage between *HLA* class II (*HLA-DQB1*, *P* = 0.000002; *HLA-DQA1*, *P* = 0.000002; *HLA-DRB1*, *P* = 0.0000003) and *TNF* genes (*TNF*, *P* = 0.00002; *LTA*, *P* = 0.003). More studies are needed to clarify this linkage because polymorphisms within the TNF gene, which is located close to the class II region, may lead to variability in TNF-*α* secretion during the leprosy infection \[[@B80]\]. This is significant, since in mycobacterial infections, TNF-*α* promotes host defense mechanisms and granuloma formation, but high concentrations of TNF-*α* are associated with immunopathology \[[@B80]\].

11. Genome-Wide and Leprosy {#sec11}
===========================

Finally, we will summarize findings from some important genome-wide association studies of leprosy. The first GWAS of leprosy susceptibility reported convincing associations with markers in six genetic loci: *HLA-DR-DQ* (rs602875, *P* = 5.4 × 10^−27^, OR = 0.67), receptor-interacting serine-threonine kinase 2 (*RIPK2*) (rs42490, *P* = 1.4 × 10^−16^, OR = 0.76), tumor necrosis factor \[ligand\] superfamily member 15 (*TNFSF15*) (rs6478108, *P* = 3.4 × 10^−21^, OR = 1.37), laccase (multicopper oxidoreductase) domain-containing 1 (*LACC1*; previously known as *C13*orf31) (rs3764147, *P* = 3.7 × 10^−54^, OR = 1.68), coiled-coil domain-containing 122 (*CCDC122*) (rs3088362, *P* = 1.4 × 10^−31^,  OR = 1.52), and nucleotide-binding oligomerization domain-containing 2 (*NOD2*) (rs9302752, *P* = 3.8 × 10^−40^, OR = 1.59) \[[@B107]\].

Subsequently, associations between leprosy and the *HLA-DR-DQ* region, *LACC1*, *CCDC122*, and the I602S functional SNP in the Toll-like receptor 1 (*TLR1*) gene were replicated in an Indian population \[[@B108], [@B109]\] and between the *HLA-DR-DQ*, *RIPK2*, *CCDC122*,*LACC1*, and*NOD2* in Vietnam \[[@B110]\].

Interesting, an association between *LACC1* (previous C13orf31) and *CCDC122* and susceptibility to Crohn\'s disease was related \[[@B111]\]. However, both genes were of unknown function and should be investigated in relation to their biologic function, which will probably clear a pathogenic mechanism of both diseases.

Recently, Yang et al. \[[@B112]\] carried out a genome-wide single nucleotide polymorphism (SNP) based linkage analysis using 23 pedigrees, each with 3 to 7 family members affected by leprosy, in China \[[@B112]\]. They suggested genomewide significant evidence for linkage on chromosome 2p14, and a suggestive evidence for linkage on chr.4q22 (rs1349350), chr.8q24 (rs1618523), and chr.16q24 (rs276990), as well as a moderate evidence for a linkage locus on chromosome 6q24--26 (rs6570858), overlapping a previously reported linkage region on chromosome 6q25-26 \[[@B112]\].

12. Conclusion {#sec12}
==============

The analysis of genetic variants in the susceptibility to infectious diseases has been a topic widely discussed. Through various studies, it is known that the environment and the virulence of the pathogen are not sufficient to explain the different immune response patterns presented in the same population against a particular pathogen. The hypothesis of the existence of a complex network of factors acting simultaneously in infectious disease is recognized, and within this context, in leprosy the host immune response is a critical factor for the onset of the disease, and the levels of this response are influenced by the interaction of different genes.

*M. leprae* can cause very different disease phenotypes in humans, probably due to individual variation in genetic profile and, consequently, in immune responses. Of the many reports of genes associated with leprosy, relatively few have been replicated in additional study populations. Further studies, involving a large number of genetic factors in populations from different parts of Brazil and the world, should be conducted to elucidate the interactions between these factors, which may be useful in the prognosis and clinical evolution of leprosy patients.

The purpose of this brief review was to highlight the importance of some immune response genes and their correlation with the development of clinical forms of leprosy, as well as their implications for disease resistance and susceptibility.

The authors are not aware of any affiliations, memberships, funding, or financial holdings that might be perceived as affecting the objectivity of this review.

###### 

Associations between HLA class I and leprosy.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Population         Study design          Sample size                  Phenotype           Serotype, allele, or haplotype   Type of association       *P* or *Pc*               Ref.
  ------------------ --------------------- ---------------------------- ------------------- -------------------------------- ------------------------- ------------------------- ------------
  Ethiopian          Case-control          20TT, 19LL, 36 controls      TT                  Aw21                             Susceptibility            *Pc* = 0.042              \[[@B12]\]

                                                                                                                                                                                 

  Indian             Case-control          30BT or TT, 40 controls      TT                  A9                               Resistance                *Pc* = 0.005              \[[@B13]\]

                                                                                                                                                                                 

  Thai               Case-control          26TT, 183 controls           TT                  A2\                              Resistance\               0.01 \< *P* \< 0.05  \    \[[@B14]\]
                                                                                            Bw17                             Susceptibility            0.01 \< *P* \< 0.05       

  Case-control       70LL, 183 controls    LL                           B7                  Susceptibility                   0.01 \< *P* \< 0.05                                 

                                                                                                                                                                                 

  Iran               Case-control          88LD, 125 controls           LL                  A1\                              Resistance\               *P* \< 0.05               \[[@B16]\]
                                                                                            B35                              Susceptibility                                      

                                                                                                                                                                                 

  Mumbai/Indian      Case-control          158LL, 150TT, 170 controls   LL\                 B-40\                            Susceptibility\           *Pc* = 0.0027  \          \[[@B17]\]
                                                                        LL\                 Aw19\                            Resistance\               *Pc* = 0.02  \            
                                                                        LL\                 A2-B40\                          Susceptibility\           *P* \< 0.00025  \         
                                                                        TT/LL\              A11-B40\                         Susceptibility\           *P* \< 0.00025  \         
                                                                        TT/LL               A24-B40                          Susceptibility            *P* \< 0.00025            

                                                                                                                                                                                 

  Japanese           Case-control          295LL, 74TL, 110 controls    LL                  B7\                              Susceptibility\           *Pc* = 0.044  \           \[[@B24]\]
                                                                                            Bw54                             Resistance                *Pc* = 0.016              

                                                                                                                                                                                 

  Korean             Case-control          157LD, 162 controls          LD                  A2\                              Resistance\               *P* = 0.03  \             \[[@B15]\]
                                                                                            A11\                             Susceptibility\           *P* = 0.03  \             
                                                                                            Aw33\                            Susceptibility\           *P* = 0.003  \            
                                                                                            Cw5                              Resistance                *P* = 0.001               

                                                                                                                                                                                 

  Indian             Case-control          65ENL, 71LL                  ENL                 A11                              Susceptibility            *Pc* = 0.0035             \[[@B18]\]

                                                                                                                                                                                 

  Indian             Case-control          68LL, 237 controls           LL                  B60                              Susceptibility            *Pc* = 0.00019             

  Case-control       138LD, 237 controls   LD                           B60                 Susceptibility                   *Pc* = 0.031              \[[@B7]\]                 

  Case-control       20BB, 237 controls    BB                           B40                 Susceptibility                   *Pc* = 0.018                                        

                                                                                                                                                                                 

  Southern Chinese   Case-control          50LL, 69 controls            LL                  B46                              Resistance                *P* \< 0.01               \[[@B19]\]

                                                                                                                                                                                 

  Turkish            Case-control          80LD, 120 controls           LD                  A9\                              Susceptibility\           *Pc* = 0.0004  \          \[[@B20]\]
                                                                                            A10\                             Susceptibility\           *Pc* = 0.0226  \          
                                                                                            Bw4\                             Susceptibility\           *Pc* = 0.00003  \         
                                                                                            Bw6\                             Susceptibility\           *Pc* = 0.00001  \         
                                                                                            Cw1\                             Susceptibility\           *Pc* = 0.0080  \          
                                                                                            Cw2\                             Susceptibility\           *Pc* = 0.0055  \          
                                                                                            A3\                              Resistance\               *Pc* = 0.0040  \          
                                                                                            B49                              Resistance                *Pc* = 0.0035             

                                                                                                                                                                                 

  Southern Indian    Case-control          32LD, 67 controls            LD                  *A*\**02:06*  \                  Susceptibility\           *Pc* = 0.000007  \        \[[@B8]\]
                                                                                            *A*\**11:02*  \                  Susceptibility\           *Pc* = 0.00001  \         
                                                                                            *B*\**51 : 10*  \                Susceptibility\           *Pc* = 0.0000005  \       
                                                                                            *B*\**18:01*  \                  Susceptibility\           *Pc* = 0.007  \           
                                                                                            *C*\**04:07*  \                  Susceptibility\           *Pc* = 1.0 × 10^−9^  \    
                                                                                            *C*\**07:03*  \                  Susceptibility\           *Pc* = 0.000001  \        
                                                                                            *C*\**04:11*                     Resistance                *Pc* = 0.001              

                                                                                                                                                                                 

  Mumbai/Indian      Case-control          103LD, 101 controls          LD                  A02\                             Susceptibility\           *Pc* = 0.0015  \          \[[@B21]\]
                                                                                            A11\                             Susceptibility\           *Pc* = 0.009  \           
                                                                                            A28\                             Resistance\               *Pc* = 0.0014  \          
                                                                                            B12\                             Resistance\               *Pc* = 0.001  \           
                                                                                            B15\                             Resistance\               *Pc* = 0.05  \            
                                                                                            B40\                             Susceptibility\           *Pc* = 7.34 × 10^−7^  \   
                                                                                            Cw7\                             Susceptibility\           *Pc* = 2.26 × 10^−5^  \   
                                                                                            Cw3                              Resistance                *Pc* = 0.0002             

  Case-control       32ML, 67 controls     ML                           *A*\**02:06*  \     Susceptibility\                  *Pc* = 7.15 × 10^−5^  \                             
                                                                        *A*\**11:02*  \     Susceptibility\                  *Pc* = 0.00001  \                                   
                                                                        *B*\**18:01*  \     Susceptibility\                  *Pc* = 0.007  \                                     
                                                                        *B*\**51:10*  \     Susceptibility\                  *Pc* = 5.29 × 10^−6^  \                             
                                                                        *C*\**04:07*  \     Susceptibility\                  *Pc* = 5.12 × 10^−9^  \                             
                                                                        *C*\**04:11*  \     Resistance\                      *Pc* = 0.001  \                                     
                                                                        *C*\**07:03*        Susceptibility                   *Pc* = 1.97 × 10^−5^                                

  Case-control       32ML, 67 controls     ML                           *A*\**11-B*\**40*   Susceptibility                   *Pc* = 0.002                                        

                                                                                                                                                                                 

  Brazilian          Case-control          224LD, 446 controls          LD                  *A*\**11*  \                     Susceptibility\           *P* = 0.0345  \           \[[@B22]\]
                                                                                            *B*\**38*  \                     Susceptibility\           *P* = 0.0402  \           
                                                                                            *C*\**12*  \                     Susceptibility\           *P* = 0.01  \             
                                                                                            *C*\**16*                        Resistance                *P* = 0.0124              

  Case-control       88LL, 48TT            LL                           *C*\**07*  \        Susceptibility\                  *P* = 0.0211  \                                     
                                                                        *B*\**35*  \        Resistance\                      *P* = 0.0156  \                                     
                                                                        *C*\**04*           Resistance                       *P* = 0.0464                                        

                                                                                                                                                                                 

  Vietnamese         family study          198 families                 LD                  *C*\**15:05*                     Susceptibility            *P* = 0.0063               

  family study       292 families          LD                           *C*\**15:05*        Susceptibility                   *P* = 8.8 × 10^−5^        \[[@B23]\]                

                                                                                                                                                                                 

  Indian             Case-control          364LD, 371 controls          LD                  *C*\**15:05*                     Susceptibility            *P* = 3.0 × 10^−8^         
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

MB: multibacillary leprosy; LL: lepromatous leprosy; BB: borderline borderline; TT: tuberculoid leprosy; ENL: erythema nodosum leprosum; LD: leprosy disease; ns: not significant; *Pc*: corrected *P* Value; Ref.: reference.

###### 

Associations between *HLA* class II and leprosy.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Population        Study design                  Sample size                      Phenotype            Serotype, allele, or haplotype                            Type of association   *P* or *Pc*         Ref.
  ----------------- ----------------------------- -------------------------------- -------------------- --------------------------------------------------------- --------------------- ------------------- ------------
  Japanese          Case-control                  295LL, 74TL, 110 controls        LL/TT\               DR2\                                                      Susceptibility\       *Pc* \< 0.008  \    \[[@B24]\]
                                                                                   LL                   DRw9                                                      Resistance            *Pc* \< 0.0001      

                                                                                                                                                                                                            

  Thai              Case-control                  32TT, 32 controls                TT                   DR2\                                                      Susceptibility\       *Pc* = 0.02  \      \[[@B27]\]
                                                                                                        DQw1                                                      Susceptibility        *Pc* = 0.008        

                                                                                                                                                                                                            

  Korean                                          157LD, 162 controls              LD                   DR1\                                                      Susceptibility\       *P* = 0.02  \       \[[@B15]\]
                                                                                                        DR2\                                                      Susceptibility\       *P* \< 0.0001  \    
                                                                                                        DR9\                                                      Susceptibility\       *P* = 0.02  \       
                                                                                                        DR4\                                                      Resistance\           *P* \< 0.0001  \    
                                                                                                        DRw53\                                                    Resistance\           *P* \< 0.0001  \    
                                                                                                        DQw1\                                                     Susceptibility\       *P* \< 0.0001  \    
                                                                                                        DQw3                                                      Resistance            *P* \< 0.0001       

                                                                                                                                                                                                            

  Turkish           Case-control                  23LL, 27BL, 50 controls          LL/BL                DR2                                                       Susceptibility        *P* = 0.015         \[[@B28]\]

                                                                                                                                                                                                            

  Asian Indian      Case-control                  23TT, 16PTB, 19 controls         TT                   *DRB1*\**15:02*                                           Susceptibility        *P* \< 0.05         \[[@B29]\]

                                                                                                                                                                                                            

  Indian            Case-control                  138LD, 237 controls              LD                   DR2\                                                      Susceptibility\       *Pc* = 0.00031  \   \[[@B7]\]
                                                                                                        DQw1\                                                     Susceptibility\       *Pc* = 0.0004  \    
                                                                                                        DQw7                                                      Susceptibility        *Pc* = 0.00031      

  Case-control      68LL, 237 controls            LL                               DR2\                 Susceptibility\                                           *Pc* = 0.0063  \                          
                                                                                   DQw1                 Susceptibility                                            *Pc* = 0.02                               

  Case-control      30BL, 237 controls            BL                               DR9\                 Susceptibility\                                           *Pc* = 0.04  \                            
                                                                                   DQw7                 Susceptibility                                            *Pc* = 0.0006                             

                                                                                                                                                                                                            

  Indian            Case-control                  28TT, 65LL, 47 controls          LL                   *DRB1*\**15*  \                                           Susceptibility\       *P* \< 0.0001  \    \[[@B33]\]
                                                                                                        *DRB1*\**15:01*  \                                        Susceptibility\       *P* \< 0.001  \     
                                                                                                        *DRB1*\**07:01*  \                                        Susceptibility\       *P* \< 0.01  \      
                                                                                                        *DRB5*\**01:01*  \                                        Susceptibility\       *P* \< 0.001  \     
                                                                                                        *DQB1*\**06:01*  \                                        Susceptibility\       *P* \< 0.0001  \    
                                                                                                        *DQA1*\**01:02*  \                                        Susceptibility\       *P* \< 0.01  \      
                                                                                                        *DQA1*\**01:03*  \                                        Susceptibility\       *P* \< 0.01  \      
                                                                                                        *DQA1*\**02:01*                                           Susceptibility        *P* \< 0.01         

  Case-control      28TT, 65LL, 47 controls       TT                               *DRB1*\**15*  \      Susceptibility\                                           *P* \< 0.01  \                            
                                                                                   *DRB1*\**15:02*  \   Susceptibility\                                           *P* \< 0.05  \                            
                                                                                   *DQB1*\**0601*  \    Susceptibility\                                           *P* \< 0.01  \                            
                                                                                   *DQB1*\**05:03*      Resistance                                                *P* \< 0.01                               

                                                                                                                                                                                                            

  Indian            Case-control                  39TT, 20PTB, 46 controls         TT                   *DRB1*\**15:02*  \                                        Susceptibility\       *P* \< 0.05  \      \[[@B34]\]
                                                                                                        Haplotype:\                                               Resistance            *P* \< 0.05         
                                                                                                        *DRB1*\**1501*-*DRB5*\**0101-DQA1*\**0102-DQB1*\**0502*                                             

                                                                                                                                                                                                            

  Indian            Case-control                  54TT, 44 controls                TT                   *DRB1*\**15*                                              Susceptibility        *Pc* = 0.0063       \[[@B35]\]

                                                                                                                                                                                                            

  Japanese          Case-control                  38LL/BL, 79LD, 50 controls       BL/LL\               *DRB1*\**02*  \                                           Susceptibility\       *P* = 0.037  \      \[[@B46]\]
                                                                                   LD                   *DRB1*\**12*                                              Resistance            *P* = 0.013         

                                                                                                                                                                                                            

  Brazilian         Case-control                  32TT, 147 controls               TT                   DR2                                                       Susceptibility        *Pc* = 0.0132       \[[@B30]\]

                                                                                                                                                                                                            

  Japanese          Case-control                  93LD, 114 controls               LD                   *DRB1*\**04:05*  \                                        Resistance\           *Pc* \< 0.05  \     \[[@B36]\]
                                                                                                        *DQA1*\**03*  \                                           Resistance\           *Pc* \< 0.05  \     
                                                                                                        *DQB1*\**04:01*                                           Resistance            *Pc* \< 0.05        

                                                                                                                                                                                                            

  Brazilian         TDT                           73 families (147 sib-pairs)      LD                   *DQB1*\**02:01*  \                                        Resistance\           *Pc* = 0.008  \     \[[@B50]\]
                                                                                                        *DQB1*\**05:01*  \                                        Susceptibility\       *Pc* = 0.008  \     
                                                                                                        *DRB1*\**7*                                               Resistance            *Pc* = 0.036        

  TDT               73 families (147 sib-pairs)   TT                               *DQB1*\**02:01*  \   Resistance\                                               *Pc* = 0.024  \                           
                                                                                   *DQB1*\**05:01*      Susceptibility                                            *Pc* = 0.024                              

                                                                                                                                                                                                            

  Egyptian          Case-control                  24LD, 30 controls                LD                   DR2\                                                      Susceptibility\       *P* = 0.032  \      \[[@B31]\]
                                                                                                        DQ1                                                       Susceptibility        *P* = 0.015         

                                                                                                                                                                                                            

  Southern Indian   TDT                           223 ASP                          TT                   *DRB1*\**15(2)*  \                                        Susceptibility\       *P* = 0.012  \      \[[@B37]\]
                                                                                                        *DRB1*\**09*                                              Resistance            *P* = 0.004         

                                                                                                                                                                                                            

  Argentinean       Case-control                  70LL, 112 controls               LL                   *DQB1*\**02:01*  \                                        Resistance            *Pc* = 0.02         \[[@B48]\]
                                                                                                        *DQB1*\**02:02*  \                                                                                  
                                                                                                        *DQB1*\**02:03*                                                                                     

  Case-control      19PB, 112 controls            TT                               *DRB1*\**04*         Resistance                                                *Pc* = 0.0192                             

                                                                                                                                                                                                            

  North Indian      Case-control                  34BT/TT, 79BL/LL, 111 controls   BL/LL                *DRB1*\**15:01*                                           Susceptibility        *P* \< 0.05         \[[@B10]\]

                                                                                                                                                                                                            

  Brazilian         Case-control                  578LD, 691 controls              LD                   *DRB1*\**04*  \                                           Resistance\           *Pc* = 0.04076  \   \[[@B38]\]
                                                                                                        *DRB1*\**07*  \                                           Resistance\           *Pc* = 0.04753  \   
                                                                                                        *DRB1*\**10*  \                                           Susceptibility\       *Pc* = 0.02102  \   
                                                                                                        *DRB1*\**12*  \                                           Resistance\           *Pc* = 0.04399  \   
                                                                                                        *DRB1*\**15*                                              Susceptibility        *Pc* = 0.02288      

  Euro-Brazilian    Case-control                  578LD, 691 controls              LD                   *DRB1*\**04*/NN^c^  \                                     Resistance\           *Pc* = 0.01  \      
                                                                                                        *DRB1*\**07*/NN^c^                                        Resistance            *Pc* = 0.01         

  Afro-Brazilian    Case-control                  578LD, 691 controls              LD                   *DRB1*\**10*/NN^c^  \                                     Susceptibility\       *Pc* = 0.024  \     
                                                                                                        *DRB1*\**15*/NN^c^                                        Susceptibility        *Pc* = 0.0002       

  Vietnam           TDT                           194 single-case families         LD                   *DRB1*\**10*  \                                           Susceptibility\       *Pc* = 0.04  \      
                                                                                                        *DRB1*\**04*                                              Resistance            *Pc* = 0.03         

                                                                                                                                                                                                            

  Argentinean       Case-control                  71LD, 81 controls                LD                   *DRB1*\**14:01*  \                                        Susceptibility\       *Pc* = 0.0011  \    \[[@B47]\]
                                                                                                        *DRB1*\**14:06*  \                                        Susceptibility\       *Pc* = 0.0011  \    
                                                                                                        *DRB1*\**08:08*  \                                        Resistance\           *Pc* = 0.0006  \    
                                                                                                        *DRB1*\**11:03*                                           Resistance            *Pc* = 0.0004       

                                                                                                                                                                                                            

  Chinese           Case-control                  305LD, 527 controls              LD                   *DRB1*\**15*  \                                           Susceptibility\       *Pc* = 0.002  \     \[[@B39]\]
                                                                                                        *DRB1*\**09*                                              Resistance            *Pc* = \<0.001      

                                                                                                                                                                                                            

  Brazilian         Case-control                  30BL, 178 controls               BL                   *DRB1*\**16:01*                                           Susceptibility        *Pc* = 0.0208       \[[@B32]\]

  Case-control      63LL, 43TT                    LL                               *DRB1*\**08*         Susceptibility                                            *Pc* = 0.0481                             

                                                                                                                                                                                                            

  Taiwanese         Case-control                  65LD 190 controls                ML                   *DRB1*\**04:05*                                           Resistance            *Pc* = \<0.0001     \[[@B49]\]

                                                                                                                                                                                                            

  Brazilian         Case-control                  17LL, 77 control                 LL                   *DRB1*\**11*                                              Resistance            *Pc* = 0.0132       \[[@B51]\]

                                                                                                                                                                                                            

  Brazilian         Case-control                  36LL, 85 control                 LL                   *DRB1*\**16*                                              Susceptibility        *Pc* = 0.0105       \[[@B40]\]

  Case-control      20TT, 85 control              TT                               *DRB1*\**14*         Susceptibility                                            *Pc* = 0.032                              
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

MB: multibacillary leprosy; PB: paucibacillary; LL: lepromatous leprosy; BL: borderline lepromatous; BB: borderline borderline; TT: tuberculoid leprosy; PTB: pulmonary tuberculosis; LD: leprosy disease; NN^c^: all not significantly different alleles collapsed into a unique group (i.e., *DRB1*\**04*, *07*, *10*, *12,* and *15*) \[[@B38]\]; ASP: affected sib-pair; ns: not significant; *Pc:* corrected *P* value; Ref.: reference.

###### 

Associations between cytokine genes and leprosy.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Population          Study design                         Sample size                                                      Phenotype   Allele, genotype, or haplotype                          Type of association          *P*                       Ref.
  ------------------- ------------------------------------ ---------------------------------------------------------------- ----------- ------------------------------------------------------- ---------------------------- ------------------------- -------------
  Brazilian           Case-control                         70LL, 85BL, 55BB, 2BT, 63TT, 10IL, 15 pure neural, 92 controls   BT/TT       *TNF-308A*                                              Resistance                   *P* = 0.005               \[[@B74]\]

                                                                                                                                                                                                                                                       

  Brazilian           Case-control                         74BT                                                             BT/TT       *TNF-308A*                                              Resistance                   ND                        \[[@B75]\]

                                                                                                                                                                                                                                                       

  Brazilian           Case-control                         210MB, 90PB, 92 controls\                                        LD\         *TNF-308A*  \                                           Resistance Susceptibility\   *P* \< 0.05  \            \[[@B76]\]
                                                           143MB, 79PB, 62 controls                                         PB\         *IL10-819T*  \                                          Susceptibility               *P* \< 0.01  \            
                                                                                                                            LD          *IL10-819TT*                                                                         *P* = 0.04                

                                                                                                                                                                                                                                                       

  Brazilian           Case-control                         43TT, 65LL, 50BB, 9IL, 240 controls                              LD\         *TNF-308A*  \                                           Resistance\                  *P* = 0.02  \             \[[@B77]\]
                                                                                                                            LL          *IL10-1082G/-819C/-592C*                                Resistance                   *P* = 0.02                

                                                                                                                                                                                                                                                       

  Brazilian           Family study\                        363LD\                                                           LD          *TNF-308A*                                              Resistance\                  *P* \< 0.04  \            \[[@B78]\]
                      case-control                         1146LD, 1036 controls                                                                                                                Resistance                   *P* \< 0.02               

                                                                                                                                                                                                                                                       

  Nepal               Case-control                         581(LL,BL,BB), 343(BT,TT); 101 controls                          LD          *TNF-308A*                                              Resistance                   *P* = 0.016               \[[@B79]\]

                                                                                                                                                                                                                                                       

  Indian              Case-control                         121LL, 107TT, 160 controls                                       LL          *TNF-308A*                                              Susceptibility               *P* = 0.02                \[[@B80]\]

                                                                                                                                                                                                                                                       

  Thai                Case-control                         24MB, 13PB, 140 controls                                         MB\         *TNF-308A*  \                                           Susceptibility\              *P* = 0.04  \             \[[@B81]\]
                                                                                                                            LD          *TNF-308GA*                                             Susceptibility               *P* = 0.04                

                                                                                                                                                                                                                                                       

  French Polynesian   Family study                         6 families                                                       LD          *IL-1 beta, TNF-alpha (1, 2),* and *TNF-alpha (A, G)*   ns                                                     \[[@B82]\]

                                                                                                                                                                                                                                                       

  Brazilian           Multi case families study            76 families                                                      LD          *TNF*\**1*  \                                           Susceptibility\              *P* = 0.0001  \           \[[@B50]\]
                                                                                                                                        *TNF*\**1/LTA*\**2*  \                                  Susceptibility\              *P* = 0.014  \            
                                                                                                                                        *TNF*\**2/LTA*\**2*                                     Resistance                   *P* = 0.001               

                                                                                                                                                                                                                                                       

  Mexican             Case-control                         62 cases, 144 controls                                           LL          *TNF-308G/A*  \                                         ns                                                     \[[@B83]\]
                                                                                                                                        *IL10-819C*                                                                                                    

                                                                                                                                                                                                                                                       

  Indian              Case-control                         449PB, 473MB, 1670 controls                                      LD          *BAT1-LTA-TNF-BTNL2*                                    Susceptibility               *P* \< 0.0001             \[[@B84]\]

                                                                                                                                                                                                                                                       

  Brazilian           Case-control\                        374 cases, 380 controls\                                         LD          *IL10-819T*                                             Susceptibility               *P* = 0.01                \[[@B86]\]
                      Meta-analysis                        2702 individuals (5 studies)                                                                                                                                                                

                                                                                                                                                                                                                                                       

  Colombian           Case-control                         100 cases, 100 controls                                          LD          *IL10-819CC*and *CT*  \                                 Susceptibility\              *P* \< 0.001  \           \[[@B87]\]
                                                                                                                                        *IL10-592CC*and *CA*  \                                 Susceptibility\              *P* \< 0.001  \           
                                                                                                                                        *IL10-819C-592C*  \                                     Susceptibility\              *P* \< 0.001  \           
                                                                                                                                        *IL10-1082A-819C-592C*                                  Susceptibility               *P* \< 0.001              

                                                                                                                                                                                                                                                       

  Brazilian           Case-control                         131PB, 166MB, 283 controls                                       LD          *IL10-3575A/-2849G/-2763C*  \                           Resistance\                  *P* = 0.005  \            \[[@B88]\]
                                                                                                                                        *IL10-3575T/-2849A/2763C*                               Susceptibility               *P* = 0.027               

                                                                                                                                                                                                                                                       

  Indian              Case-control                         144MB, 142PB, 266 controls                                       LD          *IL10-3575T/-2849G/-2763C/-1082A/-819C/-592C*  \        Resistance\                  *P* = 0.01  \             \[[@B89]\]
                                                                                                                                        *IL10-3575T/-2849G/-2763C/-1082A/-819T/-592A*           Susceptibility               *P* = 0.0002              

                                                                                                                                                                                                                                                       

  Indian              Case-control                         80 cases, 89 controls                                            LD          *IL12B 3*′*UTR 2.2*                                     Resistance                   *P* = 0.001               \[[@B91]\]

                                                                                                                                                                                                                                                       

  Korean              Case-control                         93LL, 94 controls                                                LL          *IL12RB1*  \                                            ns                                                     \[[@B92]\]
                                                                                                                                        *IFNGR1*                                                                                                       

                                                                                                                                                                                                                                                       

  Japanese            Case-control                         130LL, 46TL, 68 controls                                         LL          *IL12RB2-1035G*  \                                      Susceptibility               *P* \< 0.001  \           \[[@B93]\]
                                                                                                                                        *IL12RB2-1023G*  \                                                                   *P* \< 0.01  \            
                                                                                                                                        *IL12RB2-650delG*  \                                                                 *P* \< 0.001  \           
                                                                                                                                        *IL12RB2-464G*  \                                                                    *P* \< 0.01  \            
                                                                                                                                        *IL12RB2-1035A/-1023A/-650G/-464A*                                                   *P* \< 0.039              

                                                                                                                                                                                                                                                       

  Mexican             Case-control                         44LL, 51 controls                                                LL          *IL12 3*′*UTR 1188A/C*                                  Susceptibility               *P* \< 0.05               \[[@B94]\]

                                                                                                                                                                                                                                                       

  Mexican             Case-control                         66LL, 140 controls                                               LL          *IL12 3*′*UTR 1188A/C*                                  ns                                                     \[[@B95]\]

                                                                                                                                                                                                                                                       

  Chinese             Multiple-stage genetic association   4971 cases, 5503 controls                                        LD          *IL18RAP/IL18R1*(rs2058660)*IL12B*(rs6871626)           Susceptibility               *P* = 4.57 × 10^−19^  \   \[[@B96]\]
                                                                                                                                                                                                                             *P* = 3.95 × 10^−18^      

                                                                                                                                                                                                                                                       

  Brazilian           Case-control                         1045 cases, 1080 controls                                        LD          *IFNG+ 874T*                                            Resistance                   *P* = 0.005               \[[@B98]\]

                                                                                                                                                                                                                                                       

  Chinese             Case-control                         527 cases, 583 controls                                          LD\         *IFNG+ 874T/A*  \                                       ns\                             \                      \[[@B99]\]
                                                                                                                            LD, MB\     *IFNG(10CA),*  \                                        Susceptibility\              *P* = 0.001  \            
                                                                                                                            MB\         *IFNG(13CA)*  \                                         Susceptibility\              *P* = 0.026  \            
                                                                                                                            MB\         *IFNG(15CA)*  \                                         Susceptibility\              *P* = 0.007  \            
                                                                                                                            PB          *IFNG(17CA)*                                            Susceptibility               *P* = 0.04                

                                                                                                                                                                                                                                                       

  Brazilian           Case-control                         108 cases, 113 controls                                          PB          *IFNG+874AA*  \                                         Susceptibility\              *P* = 0.028  \            \[[@B100]\]
                                                                                                                                        *IFNG(16CA)*                                            Susceptibility               *P* = 0.019               

                                                                                                                                                                                                                                                       

  Brazilian           Case-control                         10TT, 59BB, 27LL, 98 controls                                    LD          *IFNG(15CA), (16CA),  *and*  (17CA)*                    Susceptibility               *P* = 0.01                \[[@B101]\]

                                                                                                                                                                                                                                                       

  Iranian             Case report                          3 cases                                                          LD          *IFNGR1-56T/C*                                          Susceptibility               ND                        \[[@B102]\]

                                                                                                                                                                                                                                                       

  Chinese             Case-control                         80PB, 352MB, 465 controls                                        LD          *IL4-590TC*  \                                          Resistance\                  *P* = 0.044  \            \[[@B103]\]
                                                                                                                                        *IL4-590CC*  \                                          Resistance\                  *P* = 0.01  \             
                                                                                                                                        *IL4-590C*                                              Resistance                   *P* = 0.001               

                                                                                                                                                                                                                                                       

  Indian              Case-control                         2447 cases, 1294 controls                                        LD          *IL-10*(rs1800871, rs1800872,\                          Susceptibility               *P* \< 0.05               \[[@B106]\]
                                                                                                                                        rs1554286);\                                                                                                   
                                                                                                                                        *IL-10RB*(rs3171425; rs7281762);\                                                                              
                                                                                                                                        *TGFBR2*(rs2228048, rs744751);\                                                                                
                                                                                                                                        *IL-6* (rs1800797)                                                                                             
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

MB: multibacillary; PB: paucibacillary; LL: lepromatous leprosy; BL: borderline lepromatous; BT: borderline tuberculoid; TT: tuberculoid leprosy; LD: leprosy disease; ns: not significant; ND: no data; *P* value; Ref.: reference.
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